TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02382861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist
Description: In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive pressure support ventilation
Description: In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
Study: NCT00476190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Induction: Intrathecally on day 15 or 18. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation II: Intrathecally once every 18 weeks. Continuation: Intrathecally every 18 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Induction: Intrathecally on day 15 or 18. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation II: Intrathecally once every 18 weeks. Continuation: Intrathecally every 18 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Consolidation IC: Orally on days 1-5 twice per day. Consolidation II: Orally on days 1-5 of each cycle. Continuation: Orally on days 1-5 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Consolidation IC: Orally on days 1-5 twice per day. Consolidation II: Orally on days 1-5 of each cycle. Continuation: Orally on days 1-5 of each cycle.
Study: NCT03348735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Description: Application of Lidocaine 5% patch for 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% Patch
Description: Application of Capsaicin 8% patch for

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe.
Study: NCT01948531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynomunal® gel
Description: A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
Study: NCT04362553

Intervention type: DEVICE
Intervention: wearable vital signs sensor
Description: vital signs monitoring during standard of care procedures; TTE, swan-ganz catheterization
Study: NCT00224471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK208141 vaccine
Description: 3 IM doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK208141 vaccine
Description: 3 IM doses
Study: NCT02366117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
Study: NCT00476190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-MP
Description: Induction: Orally on days 3-43 or 33-46. Consolidation IA: orally on days 1-14. Consolidation IB: orally on days 1-14. CNS Therapy: Orally on days 1-14. Consolidation II: Orally on days 1-14. Continuation: Orally on days 1-14 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-MP
Description: Induction: Orally on days 3-43 or 33-46. Consolidation IA: orally on days 1-14. Consolidation IB: orally on days 1-14. CNS Therapy: Orally on days 1-14. Consolidation II: Orally on days 1-14. Continuation: Orally on days 1-14 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Asparaginase
Description: Consolidation IC: Intravenously every 3 weeks, starting on day 8. CNS Therapy: Intravenously every 3 weeks, starting 3 weeks after the Consolidation IC dose.~Consolidation II: Intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Asparaginase
Description: Consolidation IC: Intravenously every 3 weeks, starting on day 8. CNS Therapy: Intravenously every 3 weeks, starting 3 weeks after the Consolidation IC dose.~Consolidation II: Intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Used for PH+ ALL subjects enrolled prior to May 1st 2011 only and is used continuously throughout every phase of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Used for PH+ ALL subjects enrolled prior to May 1st 2011 only and is used continuously throughout every phase of treatment.
Study: NCT02399605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: Subcutaneous abdominal electrical stimulation
Study: NCT01935375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CNM Interpersonal Psychotherapy
Description: Eight Weekly 50 minute sessions CNM Interpersonal Psychotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual is psychotherapy provided by a mental health provider
Study: NCT04718259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine
Description: The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine
Description: The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam
Study: NCT04338919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: PCI with stent implantation
Study: NCT00476190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Consolidation IC: intravenously on days 3, 4 and 5 of this cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Consolidation IC: intravenously on days 3, 4 and 5 of this cycle.
Study: NCT04338919

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: PCI with stent implantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Description: Ticagrelor plus aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor plus aspirin
Description: Ticagrelor plus aspirin
Study: NCT01681823

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PectaSol-C Modified Citrus Pectin (MCP)
Description: Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
Study: NCT02718196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Training smartphone application
Description: Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
Study: NCT00476190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Given during CNS Therapy either 8 or 10 daily treatments, on days 1-8 or 1-10, depending upon leukemia involvement in the CSF
Study: NCT04235205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)
Description: Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g) for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10mg + cholestyramine powder placebo
Description: Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg+ cholestyramine powder placebo for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)
Description: Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
Study: NCT02945553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.
Study: NCT04235205

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elobixibat placebo + cholestyramine powder placebo
Description: Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder placebo for 16 weeks
Study: NCT02945553

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microstimulation
Description: Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.
Study: NCT02119039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RGTA OTR 4120 (CACICOL20)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genteal HA eye drops
Study: NCT03159364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pathogen-specific CTLs
Description: Patients will receive approximately 1x10\^5\~1x10\^6 CTLs/kg as a single infusion via IV injection and may receive additional infusions.
Study: NCT00476190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E. coli Asparaginase
Description: Intramuscularly Day 7 of Induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E. coli Asparaginase
Description: Intramuscularly Day 7 of Induction.
Study: NCT04390516

Intervention type: DEVICE
Group type: OTHER
Intervention: COViage
Description: The COViage machine learning algorithm is designed to predict mechanical ventilation and mortality within 24 hours after hospital admission.
Study: NCT02440828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tobramycin inhalation
Description: tobramycin inhalation 300 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: NaCl 0.9% inhalation 4 ml twice daily
Study: NCT01969565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study: NCT04218305

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Level Of Fetuin A

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Level Of Fetuin A
Study: NCT01969565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT04674501

Intervention type: PROCEDURE
Intervention: Cardiac evaluation and blood sampling
Description: Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation.~The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed.~The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets.
Study: NCT02635347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Description: Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet
Description: Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
Study: NCT04519047

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).
Study: NCT00546260

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administration of iv bolus prior to angiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT060128 Potassium
Description: administration of iv bolus prior to angiography
Study: NCT02367391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Text Messages
Description: Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Usual Care. All participants receive the active medication, Varenicline.
Study: NCT02234024

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation of dairy-derived concentrated gangliosides.
Study: NCT00457158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALN optional filter
Description: J1 : ALN optional filter M3 : ALN optional filter removed
Study: NCT04212611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INFRA ORBITAL BLOCK
Description: Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L) or ropivacaine (group R).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INFRA ORBITAL BLOCK
Description: Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L) or ropivacaine (group R).
Study: NCT01609673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended.
Study: NCT03257306

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ureteral double-J stent removal using magnet
Description: Double-J ureteric stent removed using magnet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ureteral double-J stent removal using magnet
Description: Double-J ureteric stent removed using magnet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ureteral double-J stent removal using cystoscopy
Description: Double-J ureteric stent removed using cystoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ureteral double-J stent removal using cystoscopy
Description: Double-J ureteric stent removed using cystoscopy
Study: NCT02021864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3 50,000 unit
Description: vitamin D3 50,000 unit/week for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prenatal multivitamin
Description: daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prenatal multivitamin
Description: daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
Study: NCT02491528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: insulin Aspart injection
Description: Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: insulin Aspart injection (NovoRapid)
Description: Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
Study: NCT00670891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oxygen (Hyperbaric Oxygen Therapy)
Description: Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International~1. Air or Gas Embolus~2. Decompression Illness~3. Carbon Monoxide poising~4. Clostridial Myonecrosis (Gas Gangrene)~5. Necrotizing Fasciitis~6. Crush Injury (Compartment syndromes)~7. Selected Problem Wounds~8. Compromised Skin Flaps or Grafts~9. Refractory Osteomyelitis~10. Exceptional Anemia due to Blood loss~11. Osteoradionecrosis~12. Thermal Burns and Radiation Tissue Damage~13. Diabetic Wounds~14. Intra-Cranial Abscess~15. Brain Injury and other Head Trauma~16. Cerebral Palsy~17. High Altitude Sickness~18. Lyme disease
Study: NCT04460924

Intervention type: DRUG
Intervention: Integrase strand transfer inhibitors
Description: Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment

Intervention type: DRUG
Intervention: Integrase strand transfer inhibitors
Description: Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment

Intervention type: DRUG
Intervention: Integrase strand transfer inhibitors
Description: Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment

Intervention type: DRUG
Intervention: Integrase strand transfer inhibitors
Description: Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment
Study: NCT01020162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitryptiline, gabapentin
Description: For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection of the ilioinguinal nerve
Description: In general anaesthesia the nerve was identified and resected as central as possible
Study: NCT04058808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Watchers
Description: online or in a weekly wellbeing workshop, there is a fee of £12.95 per month, this is a healthy lifestyle programme based on food items having a point attached to them depending on the calorie, fat and sugar content. Each member has a specific number of points per day to use on their meals. The healthier foods have fewer points therefore you can eat more of them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slimming world
Description: online or in a weekly class, there is a fee of £5 per week. Free foods can be consumed freely are low fat healthy options, healthy extras (bread/milk/pulses) can be consumed in moderation. Higher fat, higher calorific foods have a number of SYNS attached, each person has a set number of SYNS (sins) per week to use as they wish.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leeds 'One You'
Description: a free weekly 1 hour class (run in various places across Leeds), a variety of topics are covered, from food labels to the Eat well guide. This eating plan is based on calorie counting.
Study: NCT03500419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX
Description: PTT - Penile traction therapy in the straight position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment
Description: Control group. No treatment will be given for the 6 months post-prostatectomy
Study: NCT00381706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECF
Description: epirubicin and 5-fluorouracil given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC
Description: cisplatin and irinotecan given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: oxaliplatin , leucovorin and 5-fluorouracil IV
Study: NCT03030794

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: A non-invasive method of brain stimulation that emits a magnetic pulse.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (sham)
Description: No brain stimulation will be administered.
Study: NCT01110889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine (AGO178C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine (AGO178C)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00476515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: the recommended dosage of Rituximab is 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22).
Study: NCT01796106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Description: Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth, the study lesions will be treated using the resin infiltrant Icon (DMG, Germany) according to manufactures´ instructions. Essentially, the treatment consists of the following parts: 1) isolating the tooth with a rubber dam and cleaning its surface; 2) removing/ conditioning the surface layer of the lesion (using Icon-Etch) to open the lesion body; 3) drying of the exposed porous enamel; 4) infiltrating the existing pore volume with the resin infiltrant (Icon Infiltrant); 5) light curing of the resin infiltrant; 6) repeating the infiltration step including light curing; followed by 7) finalizing using interproximal finishing/polishing strips.
Study: NCT04058808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NHS Choices
Description: a free on line programme that is based on restricting calories using the Eat well guide and encouraging physical activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5:2 diet
Description: 5 days of eating normal calories (2000 Female, 2500 Male) and 2 days eating restricted 500 calories (this may be amended depending on the patient).
Study: NCT00224471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK208141 vaccine
Description: 3 IM doses
Study: NCT01727726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: tablet/capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel XR
Description: tablet/capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet/capsule
Study: NCT04058808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individuals own personal plan
Description: the participant will explain in detail their own designed plan and this will be documented on the paper records.